AIDS by HADDAD, Lisa B. et al.
Bacterial vaginosis modifies the association between hormonal 
contraception and HIV acquisition
Lisa B. HADDAD, MD, MS, MPHa,b,*, Kristin M WALL, PhDb,c, William KILEMBE, MD, MScb, 
Bellington VWAILIKA, MSc, MDb,e, Naw Htee KHU, MPHb, Ilene BRILL, MPHd, Elwyn 
CHOMBA, MDb,f, Amanda TICHACEK, MPHb, and Susan ALLEN, MD, MPHb
aDepartment of Gynecology and Obstetrics, Emory University, School of Medicine, Atlanta, 
Georgia, USA
bRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School 
of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Emory 
University, Atlanta, GA, USA
cDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, 
USA
dDepartment of Epidemiology, Ryals School of Public Health, University of Alabama at 
Birmingham, Birmingham, Alabama, USA
eDepartment of Gynecology and Obstetrics, School of Medicine, University of Zambia, Lusaka, 
Zambia
fMinistry of Community Development, Mother and Child Health, Lusaka, Zambia
Abstract
Objective—To examine BV as an effect modifier for the association between hormonal 
contraception (HC) and incident HIV infection
Design—Serodiscordant couples enrolled in an open longitudinal cohort in Lusaka, Zambia from 
1994–2012. This analysis was restricted to couples with an HIV-positive man enrolled 
between1994–2002 when a quarterly genital tract examination and HIV testing was performed.
Methods—Multivariate Cox models evaluated the association between contraceptive method and 
HIV-acquisition, stratified by time-varying BV status.
Results—Among 564 couples contributing 1137.2 couple-years of observation, BV was detected 
at 15.5% of study visits. 22 of 106 seroconversions occurred during intervals after BV was 
detected (12 on no method/non-hormonal method (non-HC), 2 on injectables, 8 on oral 
contraceptive pills, (OCPs)). Unadjusted seroincidence rates per 100-couple-years for non-HC, 
injectable, and OCP users, respectively, during intervals with BV were 8.3, 20.8 and 31.0 and 
during intervals without BV were 8.2, 9.7 and 12.3. In the BV-positive model, there was a 
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significant increase in incident HIV among those using injectables (adjusted hazard ratio, aHR 
6.55, 95% CI 1.14–37.77) and OCPs (aHR 5.20, 95% CI 1.68–16.06) compared to non-HC. HC 
did not increase the hazard of HIV acquisition in BV-negative models. These findings persisted in 
sensitivity analyses when all covariates from the nonstratified model previously published were 
included, when other genital tract findings were excluded from the model and with the addition of 
condom-less sex and sperm on wet-prep.
Conclusions—Future research should consider a potential interaction with BV when evaluating 
the impact of HC on HIV acquisition.
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INTRODUCTION
Hormonal contraception is widely used globally for the prevention of unintended pregnancy. 
However, some have postulated that hormonal contraception may increase susceptibility to 
human immunodeficiency virus (HIV) infection.[1–3] While overall data on the association 
between combined hormonal contraceptive pills and HIV acquisition are limited, there 
appears to be no increased risk in women with use of these methods.[3] With injectable 
contraceptive use, particularly depot medroxyprogesterone acetate (DMPA), recent meta-
analyses suggest a 20–70% increased risk of HIV acquisition.[3, 4] Importantly, not all 
studies have demonstrated a consistent link between use of DMPA and HIV risk in women, 
with several well-designed studies finding no statistical association.[5–7] The World Health 
Organization (WHO) recognizes this important knowledge gap and encourages research to 
clarify the association and explore mechanisms associated with hormonal contraceptives that 
may underlie an increase in HIV transmission risk.[8, 9]
Several local factors within the vagina may increase HIV transmission risk and mediate the 
association between hormonal contraception and HIV acquisition.[10] One potential factor 
is bacterial vaginosis (BV), a condition of a polymicrobial vaginal flora with an elevated 
vaginal pH and divergence from a healthy lactobaccili dominant vaginal flora.[10, 11] There 
is a growing body of literature supporting the role of the microbiota in altering local and 
systemic immune function.[12–14] Several studies have found that HIV acquisition 
increases in the setting of BV and non-lactobaccili-dominant flora.[15–18] While there is 
growing evidence of this direct association between vaginal microbiota and HIV acquisition, 
it is unclear if vaginal microbiota may be implicated in the noted association between 
hormonal contraception and HIV risk.
Most studies suggest that combined estrogen-progestin and progestin-only hormonal 
contraception does not increase the presence of BV and some methods may even be 
protective against BV.[19–21] In a recent meta-analysis, all studies reviewed showed either a 
statistically significant decrease or no significant difference in the incidence of BV in 
hormonal contraceptive users when compared to non-hormonal contraceptive users. When 
including the three highest quality studies, they found a 10–20% reduction in the incidence 
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of BV in combined oral contraceptive users and an 18–30% reduction in DMPA users versus 
non-hormonal method users.[22] Another meta-analysis including 55 studies reported an 
approximate 25% reduction in BV in hormonal contraceptive users compared with non-
users, with this pattern similar for both combined estrogen-progestin and progestin-only 
methods.[23] These data suggest that alterations in the vaginal microflora with contraceptive 
use are not part of the mechanisms for the observed increased HIV acquisition risk with 
hormonal contraception.
Prior studies have evaluated the effect of HSV or genital tract ulcers as potential effect 
modifiers in the association between hormonal contraception and HIV acquisition in women.
[7, 24] However, no studies to date have evaluated whether BV may modify this association. 
Our objective was to leverage a large HIV discordant couple cohort to explore the 
association between hormonal contraception and HIV acquisition in women, considering BV 
as a potential effect modifier. Our previous evaluation of the cohort did not demonstrate a 
significant increase in incident HIV with oral contraceptive, injectable contraceptive or 
contraceptive implant use. We hypothesized that we would see a different association 
between hormonal contraception and incident HIV in the presence of BV. This hypothesized 
interaction between two independent potential risk factors may explain some of the 
inconsistencies in the literature that cloud our interpretation of hormonal contraception as a 
potential HIV risk factor.
METHODS
Study Design, Participants and Ethics
The study is a secondary analysis of a longitudinal cohort of heterosexual HIV 
serodiscordant couples in which the man is HIV-positive and the woman HIV-negative (M
+F-) in Lusaka, Zambia. Heterosexual married or cohabitating HIV serodiscordant couples 
were invited to enroll in an open cohort study between 1994–2012. The study recruitment,
[25, 26] intervention design, uptake of contraception immediately after an educational 
intervention,[27] impact of informed consent on knowledge and concerns about 
contraceptive methods,[28] demographics of the cohort, rates of unintended pregnancy and 
impact of contraceptive method on unintended pregnancy,[29] impact of the intervention on 
incident pregnancy,[30] patterns of contraceptive use and discontinuation,[31] impact of 
hormonal contraception on HIV acquisition risk,[7] HIV transmission to partners,[32] and 
disease progression[33] have been previously reported. The Institutional Review Boards at 
Emory University and the University of Zambia approved this study. Written informed 
consent was obtained from all participating couples.
Exposure of interest
Contraceptive method used since last visit (none/condoms only, oral contraceptive pills 
(OCPs), DMPA (150mg IM dosage), copper intrauterine device (IUD), contraceptive 
implant (Levonorgestrel implant: Norplant, Jadelle), or permanent methods (hysterectomy/
tubal ligation/vasectomy)) was recorded at baseline and three-monthly follow-up visits. The 
majority of OCPs were combined pills containing both an estrogen and progestin, with 
progesterone-only pills being primarily prescribed to breastfeeding women until children 
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were 6 months old or the minority of women with contraindications to estrogens. In our 
primary analysis, contraceptive methods were categorized as implant, injectable, or OCP 
versus non-hormonal (non-HC), including none/condoms only or permanent methods. All 
methods were provided at the research site.
Outcome of interest
The primary outcome evaluated any incident HIV infection among women, either linked or 
unlinked to the cohabiting male partner. HIV testing using rapid serologic tests was 
conducted at intervals of three-months.[26]
Baseline covariates
At enrollment, baseline demographic data was collected including age of the man and 
woman, years cohabiting, monthly income, and woman’s literacy in Nyanja. Other possible 
risk factors evaluated as covariates included number of previous pregnancies, number of 
sexual partners for the woman in the last year, and viral load (log10 copies/mL) of the 
positive male partner.
Time-varying covariates
At scheduled three-monthly (or client-initiated interim) follow-up visits, time-varying 
exposures of interest were collected including time from enrollment (0–3 months reflecting 
prior to CVCT versus >3 months, reflecting those receiving CVCT), pregnancy, self-
reported sex without a condom with study partner in past 3 months, self-reported sex with a 
condom with study partner in past 3 months, sperm present on vaginal swab wet-prep, 
candida by wet-prep, vaginal discharge on exam, general vaginal inflammation on exam, 
sexually transmitted infection (STI; gonorrhea and/or chlamydia based on purulent 
endocervical discharge and/or trichomonas based on wet-prep), bilateral inguinal 
adenopathy (BIA) on exam, and active genital or perianal ulcers for woman in past 3 months 
(by self-report or examination finding).
Effect modification evaluation
The effect modifier of interest was a time-varying diagnosis of BV. This was diagnosed by a 
wet-prep at baseline and at scheduled or client-initiated interim follow-up visits. BV was 
diagnosed with microscopy (wet-prep for clue cells, KOH prep for whiff test, and/or gram 
stain) at a routine or interim visit.
Longitudinal data collection
Participants were provided with free outpatient care and the full range of contraceptive 
methods at the research clinic. Data collection varied by type and frequency of data collected 
over 17 years of follow-up. From 1994–2002, both partners were seen every 3 months and 
underwent physical exams including RPR screening for syphilis, genital exams and wet-prep 
with repeat HIV testing of the HIV- partner. After 2002, physical exams and wet-prep 
diagnoses were performed at baseline and thereafter only if signs and symptoms of 
infections were present. Given this change in approach to only evaluating symptomatic 
individuals, we restricted this analysis to 1994–2002.
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Data analysis
Analyses were conducted with SAS v9.3 (Cary, NC). Our analytic approach was informed 
by recommendations for a rigorous and consistent analysis of the association of HC and HIV 
acquisition described by Polis et al. [34] This approach was used previously in our 
evaluation with this cohort and demonstrated no statistically significant association between 
HC and HIV acquisition in women without consideration of effect modification with BV.[7] 
All analyses were stratified and separately analyzed for intervals with BV and intervals 
without BV.
Couple-years of follow-up were calculated from enrollment until the couple was censored. 
Couples were censored when either partner died, the couples separated, the positive partner 
started ART, or if either partner was lost to follow-up. HIV incidence rates for each 
contraceptive method type were compared to the non-HC reference group using univariate 
Cox models. These rates with corresponding 95% confidence intervals were calculated as 
the number of incident infections per couple-year of follow-up, stratified by whether a 
women had a BV infection noted at the visit prior to that study interval.
Baseline and time-varying data were described by HIV acquisition status using counts and 
percentages for categorical data or means and standard deviations for continuous data. These 
descriptive analyses were calculated across all study intervals and were stratified by BV 
status.
Bivariate associations between baseline and time-varying covariates and outcome infection 
of interest were evaluated via unadjusted Cox models to generate crude hazard ratios (HRs) 
and 95% confidence intervals (CIs). Additional bivariate associations between these baseline 
and time-varying covariate were compared for the combined outcome groups 
(seroconverters and non-converters) by BV status.
Multivariate Cox models estimated the total effect of time-varying contraceptive method 
type on time to outcome infection. Covariates significantly (p<0·05) associated with the 
exposure and outcome of interest were considered as potential confounders. Variable multi-
collinearity was assessed (condition indices of 0·30 and variance decomposition proportions 
of 0·05 as cutoff criteria); if any two variables were found to be collinear, the variable with 
the weakest association with the outcome was removed. The proportional hazards 
assumption using Schoenfeld residuals and graphical methods (plots of log [-log (survival 
probability)] versus log (time)) was confirmed for time-independent covariates. Adjusted 
HRs (aHRs) and 95% CIs are presented for covariates in the final multivariate models. For 
each model, contraceptive method was forced into the final multivariable models. Breslow-
day test was used to determine the significance of an interaction by time-varying BV status.
Sensitivity analysis
We ran a sensitivity analysis including all the variables included in a non-BV stratified 
model we previously published on from this cohort[7] given potential for unidentified 
confounding in the smaller stratified samples. Similarly, we ran an additional analysis 
including all covariates in the stratified models if found to be a confounder (associated with 
exposure and outcome at <0.05) in either one or both of the strata. We also ran the analysis 
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including variables in the prior cohort evaluation[7] adding as covariates sperm on wet-prep 
and self-reported unprotected sex. We ran an analysis excluding the genital tract findings 
(infections and ulcerations) as confounders as BV was highly correlated with several of 
these findings. Further, we also ran the previously published model, excluding the genital 
tract findings.
RESULTS
Baseline demographics and rates for seroconversion (table 1)
Among the 564 couples, a total of 106 women seroconverted over 1137.2 couple-years of 
observation. BV was detected at 648 of 4183 study visits (15.5%). 22 of the seroconversions 
occurred during intervals where BV was detected at the visit prior to the seroconversion and 
84 during intervals without BV detected. Among the 4183 visits, implants were used at 17 
visits (0.4%), injectable methods at 373 visits (8.9%), OCPs at 568 visits (13.6%) and non-
hormonal methods at 3225 visits (77.1%, with copper IUD at 40 visits (0.9%), tubal ligation 
or vasectomy at 42 visits (1.0%) and no method or only condoms at 3143 visits (75.1%)).
During intervals where BV was detected, seroincidence rates per 100-couple-years were 8.3, 
20.8 and 31.0 for non-hormonal, injectable and OCP users, respectively. During intervals 
without BV detected, seroincidence rates per 100-couple-years were 8.2, 9.7 and 12.3, for 
non-hormonal, injectable and OCP users, respectively. No seroconversions occurred among 
implant users.
Bivariate analyses (table 2)
Covariates significantly associated with BV status included illiteracy to Nyanja (83% vs. 
76%), higher number of sex partners in the last year at baseline (1.09 vs. 1.03), less 
injectable contraceptive usage (5% vs 10%), increased self-reported sex without a condom in 
the past 3 months (44% vs. 38%), higher rates of sperm on wet-prep (24% vs. 17%), 
increased vaginal discharge (14% vs. 9%), increased STIs inflammation (15% vs. 6%) and 
increased BIA in the woman (8% vs 7%).
Among intervals with BV, baseline and time-varying covariates significantly associated with 
HIV incidence (non-seroconverting intervals vs, seroconverting intervals) included younger 
age of the woman (27.46 vs. 22.68), OCP use (14% vs. 36%), being in the initial 3 months 
after enrollment in CVCT cohort (2% vs. 23%), vaginal inflammation (3% vs. 14%) and 
BIA on exam (8% vs. 23%) in the past 3 months. Among the intervals without BV, being in 
the initial 3 months after enrollment in the CVCT cohort (3% vs. 14%), having a STI 
inflammation (6% vs. 13%) and BIA (7% vs. 19%) in the past 3 months were associated 
with increased HIV incidence.
Contraceptive method at follow-up was significantly associated with seroconversion only 
among those with BV, with an increase in seroconversion among those using OCPs 
compared to those using non-HC.
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Multivariate analyses (table 3)
Hormonal contraceptive method was associated with incident HIV in the multivariable 
analysis in the time-varying BV-positive models but not in the BV-negative models, where 
BV was a significant interaction term (Breslow-day test for interaction by BV: p<0.001). In 
the BV-positive model, when controlling for women’s age (per year increase), vaginal 
inflammation in the past 3 months, and time interval since enrollment (0–3 months versus 3 
months), there was a significant increase in HIV acquisition among those using injectable 
contraception (aHR 6.55, 95% CI 1.14–37.77) and OCPs (aHR 5.20, 95% CI 1.68–16.06) 
compared to the non-HC group. In the BV-negative model, use of the implant, injectables 
and OCPs did not have any increased hazards of HIV acquisition compared to the non-HC 
group, when controlling for time interval since enrollment (0–3 months vs. >3 months), STI 
in the past 3 months, and BIA in the past 3 months.
Sensitivity analysis
Overall, the results from the sensitivity analyses led to similar conclusions. In the 
multivariate models limited to including all the covariates that were confounders in the non-
stratified evaluation previously published, we found a similar significant increase in HIV 
acquisition with use of injectable contraception (aHR 6.58, 95% CI 1.06–40.87) and OCPs 
(aHR 4.66, 95% CI 1.45–14.96) compared to non-HC use for the BV positive model. 
Similarly when controlling for women’s age, time interval since enrollment, vaginal 
inflammation, inflammatory STI or BIA in last 3 months, the covariates that were identified 
as potential confounders in either or both strata, we found a similar increase in HIV 
acquisition with injectable (aHR 5.91, 95% CI 1.02–34.97) and OCP use. (aHR 4.78, 95% 
CI 1.52, 15.01). When excluding other genital tract findings, there was a significant increase 
in HIV acquisition with OCP use compared to non-HC use (aHR 5.7, 95% CI 1.9, 17.2) in 
the BV positive model with the association among injectable users approaching significance 
(aHR 5.4, 95% CI 0.96, 30.4, p=0.056). When sperm on wet prep and condomless sex were 
added to the model, a similar increase in HIV acquisition was noted with injectable (aHR 
9.2, 95% CI 1.3, 62.5) and OCP use (aHR 7.6, 95% CI 1.9, 31.0) compared to non-HC use 
in the BV models. Lastly, with all the confounders from the published analysis included and 
excluding the genital tract findings, there was a significant increase in HIV acquisition 
among injectable (aHR 5.9, 95% CI 1.02, 33.9) and OCP (aHR 5.6, 95% CI 1.9, 17.1) users 
compared to non-HC users in the BV positive model. There was no association between use 
of HC and HIV acquisition in the non-BV models compared to non-HC use in any of the 
sensitivity analyses.
DISCUSSION
We present results indicating BV as a potent effect-modifier of the association between HC 
and HIV acquisition that may have large global health implications. While increasing 
evidence has supported a direct role for BV in increasing HIV acquisition risk, our results 
suggest that this impact is amplified in the setting of HC use, specifically injectables and 
OCPs, with increased hazard ratios greater than 5 for HIV acquisition in the setting of BV 
for injectables and OCPs compared to non-HC use. Though our numbers were small and 
confidence intervals large, these findings highlight the importance of acknowledging the role 
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of the vaginal environment in HIV acquisition risk and evaluating the genital tract 
environment in future studies investigating the association between hormonal contraceptives 
and HIV risk.
Proposed mechanisms for the association between HC and HIV have included alterations in 
the local genital tract immunologic milieu and the composition of key HIV target immune 
cells, as well as alterations in vaginal epithelial tight junctions and mucosal permeability.
[35–37] Recent evidence has pointed towards the gut microbiota and the hormonal 
environment as working synergistically to influence the development of disease states such 
as obesity, diabetes and certain cancers.[38] While a significant amount of literature has 
been building to explore the importance of the gut microbiota, our current understanding of 
the significance of the vaginal microenvironment is relatively limited. HC may have a 
differential impact to amplify the effect of the microbiota on the vaginal epithelium and 
immune environment. Future studies are needed to elucidate the mechanism for this 
interaction.
While epidemiologic studies have not previously explored this interaction, a recent study by 
Fichorova et al[10] compliments our findings. Those results demonstrated that the 
immunomodulatory changes attributed to different hormonal contraceptives are dependent 
on the genital tract microenvioronment. Specifically, they report an increase in RANTES 
(regulated upon activation, normal T-cell expressed, and secreted), a chemokine that has 
been associated with increased HIV acquisition, among OCP users in the setting of BV, a 
finding that is mechanistically consistent with our observations. Although the consensus 
from the literature suggests no association between OCP use and HIV risk,[3] the reduction 
in BV among OCP users and differences in OCP adherence may have diluted any significant 
results. In the context of the demonstrated effect-modification potential of BV reported here, 
re-evaluation of those findings, if possible, is warranted.
The prevalence of BV is variable based on the clinical setting and may vary by race and 
behavioral practices. [39] While the prevalence may be underestimated since many women 
are asymptomatic, the greatest burden of BV is noted in sub-Saharan Africa.[40] Further, the 
sensitivity and specificity of clinical techniques are variable in the diagnosis of BV. For 
example, using Amsel’s criteria with a wet-prep, which can be done easily as a point-of-care 
approach, yet is only about 70% sensitive for BV.[41] The presence of clue cells on wet 
prep, is highly sensitive and specific for BV.[42] Nugent scores from a gram stain, currently 
considered the gold standard for diagnosis for BV diagnosis, may have greater sensitivity, 
but can be subject to variability in interpretation. Utilizing more sensitive microbiome 
techniques, such as 16s gene rRNA sequencing, offers an opportunity to understand the 
microenvironment at the level of specific microbial species and define microbial diversity 
with more specific methodology. While historically symptomatic BV has been attributed to 
Gardnerella vaginalis, these newer technologies have identified other bacteria associated 
with dysbiotic vaginal microbial states including Atopobium vaginae, Lactotrichia amnionii, 
Megasphaera, and members of the Clostridiales sometimes referred to as BV-associated 
bacteria (BVAB).[11, 43–45] Further, as recent studies have suggested that specific 
microbacteria in the vaginal environment may have a differential impact on the local 
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immune environment and HIV risk[45] it is important to explore this interaction using these 
more sensitive techniques.
This study has several notable limitations. Our biggest limitation is the small number of 
women using contraception who seroconverted with BV detected. While even with this 
reduced power, we find a significant association; the stability of this finding weighs heavily 
on a small number of observations. Even during the years where we conducted routine 
examinations every 3 months, we may be missing episodes of BV, due to the possible shifts 
between flora considered normal and flora considered intermediate or abnormal 
demonstrated in some studies.[46] This misclassification bias would primarily impact the 
association between contraception and HIV during the interval assessment without BV 
detected. Additionally, we use several criteria in diagnosing BV, which may increase our 
sensitivity while reducing the specificity of our BV diagnoses. This could lead to 
misclassification. The generalizability of these results may be limited as this cohort consists 
of jointly tested and counseled HIV discordant couples who often adopt condom use 
following counseling with a corresponding reduction in transmission and seroconversion 
rates. While we aimed to control for the impact of condom non-use as a potential 
confounder, both sperm on wet-prep and self-reported unprotected sex have limitations in 
their ability to detect unprotected coital events, thus some degree of unmeasured 
confounding is possible. Given these limitations, our results should be interpreted with 
caution and we encourage future studies to systematically evaluate BV as a modifier in 
future studies.
While this evaluation begins to elucidate some of the diversity noted in epidemiologic 
studies, many unanswered questions remain. It is unclear if the changes attributed to BV that 
lead to increased acquisition risk and modification of the HC-HIV association are consistent 
among BV-symptomatic compared to asymptomatic women. It is also unknown if treatment 
of BV will alter these associations. For example, treatment of asymptomatic BV during 
pregnancy does reduce the risk of preterm delivery associated with BV.[47] As BV is often 
recurrent, exploration of the role of suppressive or periodic presumptive treatment for BV on 
biologic and clinical outcomes is warranted.[48] We must leverage newer sequencing 
approaches to effectively explore the role of individual taxa or microbial communities of 
these relationships utilizing rigorous epidemiologic methodology.[49] And lastly, we must 
explore alternative explanations for the findings we report. For example, is there something 
else about individuals who get BV that predisposes them to having increased risk with 
hormonal contraceptive use, such as biologic or behavioral factors?
In conclusion, our findings suggest an association between HIV acquisition and HC use, 
specifically OCPs and injectables, among individuals with BV. Current guidelines do not 
restrict the use of contraceptive methods for women at high-risk for HIV. The newest WHO 
recommendations specifically recommend that providers discuss the potential for increased 
acquisition with the use of DMPA.[50] An individual’s contraceptive choice is influenced by 
many factors, and ultimately should remain with each woman in consultation with her 
provider. Data on alternative contraceptive options are critical for adequate counseling on 
relative risks for contraceptive use. Further, the vaginal microenvironment cannot be 
overlooked in the field of reproductive health and HIV, especially given recent data on the 
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impact of Gardenerella on antiretroviral drug concentrations used for pre-exposure 
prophylaxis effectiveness as well the possible increased risk of human papilloma virus 
(HPV) with non-lactobacillus dominant flora.[51, 52] Future research is needed to further 
explore the interaction between BV and HC on HIV acquisition. If this interaction persists 
among other studies, identification of BV may help tailor family planning discussions to 
appropriately counsel individuals on their risk. Further, periodic testing and treatment among 
asymptotic women at high-risk for HIV and counseling women on the symptoms of BV may 
be important preventative strategies among reproductive aged women.
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